University of Arizona-focused venture capital fund has invested in an optics startup developing laser-based countermeasures to protect military and civilian aircraft from missiles.
UAVenture Capital’s undisclosed investment in CMLaser Technologies Inc. is the fund’s 15th portfolio investment in just over two years.
Based on an invention of longtime UA optics professor Nasser Peyghambarian and patented by the UA, CMLaser Technologies Inc. intends to commercialize laser-based countermeasures capable of detecting and defeating missile attacks.
The size of the UAVenture fund’s investment in CMLaser was not disclosed, but the fund’s investments have averaged about $2 million each, fund co-founder and CEO Fletcher McCusker said.
CMLaser is just the latest venture for Peyghambarian, who is chair of photonics and lasers at the UA and a professor of materials science as well as optics.
UA President Robert C. Robbins called Peyghambarian “a true superstar” in a statement announcing the investment.
“The Wyant College of Optical Sciences has an incredibly strong tradition of innovation in technologies that contribute to our national security and public safety,” Robbins said.
Major defense contractors have been making onboard aircraft missile-defense systems for decades. So-called directional infrared countermeasures (DIRCM) use directed pulses of energy to confuse or jam the seekers in heat-seeking infrared missiles.
Northrop Grumman makes laser-based DIRCM systems and says it has installed 1,500 such systems on more than 80 types of fixed-wing and rotary aircraft.
AZCERT aiding COVID-19 effort
A Tucson-based drug-safety organization is making a key medication-safety tool available for free to help guide medical providers battling COVID-19.
The Arizona Center for Education and Research on Therapeutics (AZCERT), a nonprofit founded and led by former UA College of Medicine Dean Dr. Raymond Woosley, is making its MedSafety Scan web-based decision support system, available free to medical professionals around the world, especially those treating high risk COVID-19 patients.
